20 articles
New research reveals how the cholesterol medication bempedoic acid directly activates PPARΞ±, boosting fat metabolism beyond its known effects.
Baxdrostat becomes the first-in-class aldosterone synthase inhibitor approved to treat resistant hypertension alongside existing drugs.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
Tebipenem pivoxil becomes the first oral carbapenem approved in the US, offering a non-IV option for serious UTIs.
Breakthrough study reveals sepiapterin dramatically outperforms existing PKU therapy, offering hope for better metabolic control.
Master the advanced molecular architecture of AMPK β from isoform-specific signaling and spatial compartmentalization to emerging pharmacological strategies targeting the energy sensor at the heart of longevity biology.
Experimental diabetes drug IC7Fc reduces cholesterol and artery plaque buildup, offering cardiovascular benefits even without weight loss.
A landmark 500-patient RCT finds sodium bicarbonate offers no benefit over placebo for critically ill adults with metabolic acidosis and shock.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
Columbia University tested whether the diabetes drug metformin could slow memory loss in people with mild cognitive impairment.
Veterinary sedative medetomidine increasingly adulterates street fentanyl, causing severe cardiac effects and heightened overdose risk.
Ketone body Ξ²-OHB prevents sepsis-induced liver damage by modifying antioxidant enzyme SOD2, offering new therapeutic approach.
New research shows diabetes and weight-loss medications slow alcohol absorption, making people feel less intoxicated and potentially reducing drinking.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
Sodium propionate reduced liver inflammation and fat accumulation in diabetic mice fed high-fat, AGE-rich diets through multiple protective mechanisms.
Meta-analysis of 106,395 patients reveals GLP-1 receptor agonists increase risk of gallstones by 46% and GERD by 119%.
Natural polyketide from marine bacteria enhances cholesterol removal and improves fat metabolism in liver cells and mice.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
New research reveals semaglutide's liver benefits work independently of weight loss through specialized liver blood vessel cells.
